Current Opinion in Endocrinology and Diabetes was launched in 1994, with Obesity added to the title in 2007. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The fields of endocrinology and diabetes are divided into 12 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce one of the Journal's Section Editors for this issue.
Dr Vaidya is the Director of the Center for Adrenal Disorders at Brigham and Women's Hospital, USA. He oversees the multi-disciplinary clinical care of patients with all forms of adrenal hormonal and neoplastic disorders. Dr Vaidya's research lab investigates the causes and consequences of adrenal neoplasia and how adrenal hormone dysregulation can influence cardiometabolic risk.
David Handelsman is Professor of Reproductive Endocrinology and Andrology at the University of Sydney, inaugural Director of the ANZAC Research Institute and head of Andrology Department, Concord Hospital, Sydney, Australia. His interests in andrology (male reproductive health, medicine and biology) involve basic, clinical, and public health research centred on the physiology, pharmacology, and toxicology of androgens. Recent research has focused on genetic mouse models of tissue-specific androgen action, steroid mass spectrometry, sports endocrinology and anti-doping science, clinical pharmacology of androgens in ageing, and the misuse and abuse of androgens.